AU2021327782A1 - Functional ionizable phospholipids - Google Patents

Functional ionizable phospholipids Download PDF

Info

Publication number
AU2021327782A1
AU2021327782A1 AU2021327782A AU2021327782A AU2021327782A1 AU 2021327782 A1 AU2021327782 A1 AU 2021327782A1 AU 2021327782 A AU2021327782 A AU 2021327782A AU 2021327782 A AU2021327782 A AU 2021327782A AU 2021327782 A1 AU2021327782 A1 AU 2021327782A1
Authority
AU
Australia
Prior art keywords
ionizable
unsubstituted
substituted
alkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021327782A
Other languages
English (en)
Inventor
Qiang Cheng
Shuai LIU
Daniel J. Siegwart
Tuo WEI
Xueliang Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of AU2021327782A1 publication Critical patent/AU2021327782A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C07F9/106—Adducts, complexes, salts of phosphatides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021327782A 2020-08-21 2021-08-23 Functional ionizable phospholipids Pending AU2021327782A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063068944P 2020-08-21 2020-08-21
US63/068,944 2020-08-21
PCT/US2021/047203 WO2022040641A2 (en) 2020-08-21 2021-08-23 Functional ionizable phospholipids

Publications (1)

Publication Number Publication Date
AU2021327782A1 true AU2021327782A1 (en) 2023-03-23

Family

ID=80323210

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021327782A Pending AU2021327782A1 (en) 2020-08-21 2021-08-23 Functional ionizable phospholipids

Country Status (7)

Country Link
US (1) US20230320994A1 (https=)
EP (1) EP4199934A4 (https=)
JP (1) JP7849049B2 (https=)
CN (1) CN117355335A (https=)
AU (1) AU2021327782A1 (https=)
CA (1) CA3189905A1 (https=)
WO (1) WO2022040641A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024511463A (ja) * 2021-03-22 2024-03-13 リコード セラピューティクス，インク． 細胞への標的送達のための組成物および方法
JP2024511437A (ja) 2021-03-23 2024-03-13 リコード セラピューティクス，インク． ポリヌクレオチド組成物、関連製剤、およびその使用方法
WO2023218420A1 (en) 2022-05-13 2023-11-16 Janssen Pharmaceuticals, Inc. Mrna compositions for inducing latent hiv-1 reversal
EP4385523A1 (en) * 2022-12-14 2024-06-19 Beijing Jitai Pharmaceutical Technology Co., Ltd. Lipid-based topical injection formulations
WO2024124660A1 (zh) * 2022-12-14 2024-06-20 北京剂泰医药科技有限公司 脂质基质局部注射制剂
KR20250124204A (ko) * 2022-12-23 2025-08-19 턴 바이오테크놀로지스 인코포레이티드 이중 지질 구조
EP4680595A2 (en) 2023-03-15 2026-01-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2024192291A1 (en) 2023-03-15 2024-09-19 Renagade Therapeutics Management Inc. Delivery of gene editing systems and methods of use thereof
WO2024250133A1 (zh) * 2023-06-05 2024-12-12 安徽医科大学第一附属医院 肺靶向纳米胶束、制备方法及应用
CN117180196B (zh) * 2023-08-09 2025-11-18 福建师范大学 一种抗原适配型的疫苗佐剂体系及其在制备新冠和猴痘疫苗中的应用
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025155753A2 (en) 2024-01-17 2025-07-24 Renagade Therapeutics Management Inc. Improved gene editing system, guides, and methods
WO2025166238A1 (en) 2024-01-31 2025-08-07 Orna Therapeutics, Inc. Fast-shedding polyethylene glycol lipids
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4774350A (en) * 1985-08-30 1988-09-27 Kao Corporation Phosphoric ester
DE4111105A1 (de) * 1991-04-05 1992-10-08 Max Planck Gesellschaft Neue erucyl-, brassidyl- und nervonylderivate
JPH06157560A (ja) * 1992-11-26 1994-06-03 Toyo Ink Mfg Co Ltd リン脂質系界面活性剤及びその製造方法
AU9263298A (en) 1997-08-18 1999-03-08 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Phospholipid analogue compounds
ATE371680T1 (de) * 2002-01-16 2007-09-15 Biocompatibles Uk Ltd Polymerkonjugate
DE10207178A1 (de) 2002-02-19 2003-09-04 Novosom Ag Komponenten für die Herstellung amphoterer Liposomen
UA99434C2 (ru) * 2005-12-19 2012-08-27 Аетерна Центаріс Гмбх Применение производных алкилфосфолипидов со сниженной цитотоксичностью
DE102006028983A1 (de) 2006-06-23 2007-12-27 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Phosphorsäurediesteramide
JP5488121B2 (ja) 2010-03-31 2014-05-14 日油株式会社 経皮吸収促進及び／又は保湿性向上作用を示す剤、並びに化粧料
FR2966727B1 (fr) * 2010-11-03 2013-04-12 Oreal Utilisation comme antipelliculaire de polymeres phospholipidiques
FR2990206B1 (fr) * 2012-05-07 2014-06-06 Commissariat Energie Atomique Nouveaux composes bifonctionnels utiles comme ligands de l'uranium(vi), leurs procedes de synthese et leurs utilisations
WO2017059057A1 (en) * 2015-09-30 2017-04-06 The Regents Of The University Of California Nano-adhesive and surface primer compound and use thereof
HRP20220652T1 (hr) * 2015-12-10 2022-06-24 Modernatx, Inc. Pripravci i postupci unosa terapijskih sredstava
CA3024129A1 (en) 2016-05-16 2017-11-23 The Board Of Regents Of The University Of Texas System Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids

Also Published As

Publication number Publication date
EP4199934A2 (en) 2023-06-28
WO2022040641A3 (en) 2022-03-17
EP4199934A4 (en) 2024-09-04
JP2023538144A (ja) 2023-09-06
CN117355335A (zh) 2024-01-05
WO2022040641A2 (en) 2022-02-24
JP7849049B2 (ja) 2026-04-21
US20230320994A1 (en) 2023-10-12
CA3189905A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
US20230320994A1 (en) Functional ionizable phospholipids
Buck et al. Lipid-based DNA therapeutics: hallmarks of non-viral gene delivery
Moss et al. Lipid nanoparticles for delivery of therapeutic RNA oligonucleotides
Kaczmarek et al. Advances in the delivery of RNA therapeutics: from concept to clinical reality
US11464870B2 (en) Lipid nanoparticles for in-vivo drug delivery, and uses thereof
KR101168440B1 (ko) 지질 캡슐화된 간섭 ｒｎａ
Navarro et al. Micelle-like nanoparticles as carriers for DNA and siRNA
JP6640750B2 (ja) カチオン性脂質
Draghici et al. Synthetic nucleic acid delivery systems: present and perspectives
US9730893B2 (en) Lipid assemblies comprising anionic lysolipids and use thereof
KR102888610B1 (ko) 지질 나노입자
KR102537540B1 (ko) 만노스를 포함하는 지질 나노입자 또는 이의 용도
CN101970687A (zh) 用于体内基因输送的自组装胶束样纳米颗粒
JP2010263920A (ja) 標的化リポゾーム遺伝子送達
Popoola et al. Lung-specific mRNA delivery enabled by sulfonium lipid nanoparticles
Zadory et al. Current knowledge on the tissue distribution of mRNA nanocarriers for therapeutic protein expression
Zhu et al. Guanidinium-rich lipopeptide-based nanoparticle enables efficient gene editing in skeletal muscles
Dutta et al. Symbiotic self-assembly strategy toward lipid-encased cross-linked polymer nanoparticles for efficient gene silencing
JPWO2022040641A5 (https=)
Blagbrough et al. Asymmetrical N 4, N 9-diacyl spermines: SAR studies of nonviral lipopolyamine vectors for efficient siRNA delivery with silencing of EGFP reporter gene
Heinze et al. Novel cationic lipids based on malonic acid amides backbone: transfection efficacy and cell toxicity properties
Metwally et al. Efficient silencing of EGFP reporter gene with siRNA delivered by asymmetrical N 4, N 9-diacyl spermines
Miller Delivering the promise of small ncRNA therapeutics
Fang Enabling oligonucleotide-based therapeutics for non-liver disease targets
Wang et al. Reversible, covalent DNA condensation approach using chemical linkers for enhanced gene delivery